Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer

Inclusion Criteria

• •Subjects must fulfill all of the following criteria to be eligible for study entry:
• •Signed informed consent
• •At least 18 years of age
• •Histologically confirmed metastatic colorectal adenocarcinoma of the colon or rectum
• •Resected or biopsied primary tumors or metastatic site will serve as the basis for histologic confirmation.
• •Measurable disease (defined as at least one dimension \>2 cm \[\>1 cm on spiral CT scans\])
• •ECOG performance status of 0 or 1
• •Life expectancy \>3 months
• •Use of an effective means of contraception in men and in women of childbearing potential
• •Ability to comply with study and follow-up procedures